Predictive variables at baseline in ASAS40 responders, ASAS20 nonresponders, and patients who discontinued because of lack of adalimumab effectiveness.
| Predictors | ASAS40 Responders, n = 633 | ASAS20 Nonresponders, n = 264 | Patients Who Discontinued Because of Lack of Effectiveness, n = 13 |
|---|---|---|---|
| Age, yrs, mean ± SD | 41.3 ± 11.2 | 47.5 ± 11.4 | 45.8 ± 12.4 |
| CRP, mg/dl, mean ± SD* | 2.3 ± 2.6 | 1.6 ± 2.3 | 1.5 ± 1.9 |
| HLA-B27-positive, % | 83 | 74 | 69 |
| Prior TNF antagonist therapy, % | 18 | 42 | 46 |
| BASFI (0–10), mean ± SD | 5.4 ± 2.1 | 5.4 ± 2.5 | 6.6 ± 2.2 |
| BASMI (0–10), mean ± SD | 3.9 ± 2.2 | 4.5 ± 2.4 | 4.5 ± 2.1 |
↵* Reference value 0.4 mg/dl. ASAS20: Assessment in Spondyloarthritis International Society 20% response, ASAS40: Assessment of Spondyloarthritis International Society 40% response, BASFI: Bath Ankylosing Spondylitis Functional Index, BASMI: Bath Ankylosing Spondylitis Metrology Index, CRP: C-reactive protein, TNF: tumor necrosis factor